Shilpa Medicare Intrinsic Value
Shilpa Medicare (SHILPAMED) median intrinsic value is ₹896.50 from 9 valuation models (range ₹148–₹1230), vs current price ₹491.80 — +82.3% upside (Trading Below Calculated Value), margin of safety 45.1%. Browse SHILPAMED income statement for revenue, profit, balance sheet and cash flow data.
SHILPAMED Valuation Methods Summary — DCF, Graham Number & P/E
Shilpa Medicare intrinsic value across 9 models vs current price ₹491.80 — upside/downside and value range per method. Also explore SHILPAMED price trends to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹484.88 | ₹387.90 - ₹581.86 | -1.4% | EPS: ₹22.04, Sector P/E: 22x |
| Book Value Method | asset | ₹1229.50 | ₹1106.55 - ₹1352.45 | +150.0% | Book Value/Share: ₹1295.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹983.60 | ₹885.24 - ₹1081.96 | +100.0% | Revenue/Share: ₹964.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹983.60 | ₹885.24 - ₹1081.96 | +100.0% | EBITDA: ₹660.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹896.50 | ₹717.20 - ₹1075.80 | +82.3% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹147.54 | ₹132.79 - ₹162.29 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹340.52 | ₹306.47 - ₹374.57 | -30.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹983.60 | ₹885.24 - ₹1081.96 | +100.0% | ROE: 16.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹801.52 | ₹721.37 - ₹881.67 | +63.0% | EPS: ₹22.04, BVPS: ₹1295.50 |
SHILPAMED Intrinsic Value vs Market Price — All Valuation Models
Shilpa Medicare fair value range ₹148–₹1230 vs current market price ₹491.80 across 9 valuation models. For current market price and key ratios, visit SHILPAMED share price screener.
SHILPAMED Intrinsic Value Analysis — Undervalued or Overvalued?
Shilpa Medicare median intrinsic value ₹896.50, current price ₹491.80 — Trading Below Calculated Value by 82.3%, margin of safety 45.1%.
What is the intrinsic value of SHILPAMED?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Shilpa Medicare (SHILPAMED) is ₹896.50 (median value). With the current market price of ₹491.80, this represents a +82.3% variance from our estimated fair value.
The valuation range spans from ₹147.54 to ₹1229.50, indicating ₹147.54 - ₹1229.50.
Is SHILPAMED undervalued or overvalued?
Based on our multi-method analysis, Shilpa Medicare (SHILPAMED) appears to be trading below calculated value by approximately 82.3%.
SHILPAMED Financial Health — Key Ratios vs Industry Benchmarks
Shilpa Medicare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.17 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.52x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SHILPAMED Cash Flow Quality — Operating & Free Cash Flow
Shilpa Medicare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹132 Cr | ₹33 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹137 Cr | ₹52 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹180 Cr | ₹64 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹105 Cr | ₹-38 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹47 Cr | ₹-155 Cr | Positive Operating Cash Flow | 6/10 |